OBJECTIVE: The study evaluated the effectiveness of autologous hematopoietic stem cell transplantation (AHSCT) in the treatment of lymphoblastic lymphoma (LL). METHODS: We retrospectively analyzed the data from 41 patients with chemotherapy-sensitive LL who underwent hematopoietic stem cell transplantation (HSCT) from December 1989 to December 2009 in a single institution. RESULTS: HSCT was conducted as first-line consolidation therapy and salvage therapy in 36 and 5 patients, respectively. The median follow-up was 97.1 months (range, 24.6-173.1 months). The 5-year overall survival (OS) and event-free survival (EFS) rate were 64% and 47% for the initially treated patients, respectively, and were both 20% for the relapsed ones. Bone marrow (BM) involvement and chemotherapy cycles prior to transplantation were identified as significant prognostic factors for EFS in multivariate analysis. CONCLUSIONS: These results confirm that AHSCT is a reasonable option for chemotherapy-sensitive LL patients in first complete remission (CR1).
OBJECTIVE: The study evaluated the effectiveness of autologous hematopoietic stem cell transplantation (AHSCT) in the treatment of lymphoblastic lymphoma (LL). METHODS: We retrospectively analyzed the data from 41 patients with chemotherapy-sensitive LL who underwent hematopoietic stem cell transplantation (HSCT) from December 1989 to December 2009 in a single institution. RESULTS: HSCT was conducted as first-line consolidation therapy and salvage therapy in 36 and 5 patients, respectively. The median follow-up was 97.1 months (range, 24.6-173.1 months). The 5-year overall survival (OS) and event-free survival (EFS) rate were 64% and 47% for the initially treated patients, respectively, and were both 20% for the relapsed ones. Bone marrow (BM) involvement and chemotherapy cycles prior to transplantation were identified as significant prognostic factors for EFS in multivariate analysis. CONCLUSIONS: These results confirm that AHSCT is a reasonable option for chemotherapy-sensitive LL patients in first complete remission (CR1).
Authors: B D Cheson; S J Horning; B Coiffier; M A Shipp; R I Fisher; J M Connors; T A Lister; J Vose; A Grillo-López; A Hagenbeek; F Cabanillas; D Klippensten; W Hiddemann; R Castellino; N L Harris; J O Armitage; W Carter; R Hoppe; G P Canellos Journal: J Clin Oncol Date: 1999-04 Impact factor: 44.544
Authors: A Reiter; M Schrappe; W D Ludwig; M Tiemann; R Parwaresch; M Zimmermann; E Schirg; G Henze; G Schellong; H Gadner; H Riehm Journal: Blood Date: 2000-01-15 Impact factor: 22.113
Authors: Dieter Hoelzer; Nicola Gökbuget; Werner Digel; Thomas Faak; Michael Kneba; Regina Reutzel; Joanna Romejko-Jarosinska; Jacek Zwolinski; Jan Walewski Journal: Blood Date: 2002-06-15 Impact factor: 22.113
Authors: J W Sweetenham; G Santini; W Qian; M Guelfi; N Schmitz; S Simnett; A Nagler; H Holte; S Kvaloy; P Bruzzi; A H Goldstone Journal: J Clin Oncol Date: 2001-06-01 Impact factor: 44.544
Authors: K W Song; M J Barnett; R D Gascoyne; M Chhanabhai; D L Forrest; D E Hogge; J C Lavoie; S H Nantel; T J Nevill; J D Shepherd; C A Smith; H J Sutherland; C L Toze; N J Voss; J M Connors Journal: Ann Oncol Date: 2006-12-08 Impact factor: 32.976
Authors: P Morel; E Lepage; P Brice; B Dupriez; M F D'Agay; P Fenaux; B Gosselin; F Bauters; C Gisselbrecht Journal: J Clin Oncol Date: 1992-07 Impact factor: 44.544
Authors: E Jabbour; S Koscielny; C Sebban; N Peslin; C Patte; T Gargi; P Biron; C Fermé; J H Bourhis; J M Vantelon; P Arnaud; V Ribrag Journal: Leukemia Date: 2006-05 Impact factor: 11.528
Authors: B N Nathwani; L W Diamond; C D Winberg; H Kim; R M Bearman; J H Glick; S E Jones; R A Gams; N I Nissen; H Rappaport Journal: Cancer Date: 1981-12-01 Impact factor: 6.860